Health-related quality of life in long-term breast cancer survivors: differences by adjuvant chemotherapy dose in cancer and leukemia group B study 8541

Cancer

Volumn 115, Issue 5, 2009, Pages 1109-1120

  Paskett, Electra ^a   Herndon II, James ^b   Donohue, Kathleen ^b   Naughton, Michelle ^c   Grubbs, Stephen ^d   Pavy, Michael ^e   Hensley, Martee ^f   Stark, Nancy ^c   Kornblith, Alice ^g   Bittoni, Marisa ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b DUKE UNIVERSITY   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

^d HELEN F GRAHAM CANCER CENTER   (United States)

^e Southeast Cancer Control Consortium Inc   (United States)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^g DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Breast cancer; Chemotherapy; Quality of life; Survivorship

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER FATIGUE; CANCER SURVIVOR; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG MEGADOSE; FEMALE; FOLLOW UP; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MASTECTOMY; MENOPAUSAL SYNDROME; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; UNIVARIATE ANALYSIS; WELLBEING;

ADULT; AGE FACTORS; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COMORBIDITY; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; EDUCATIONAL STATUS; FEMALE; HEALTH STATUS; HUMANS; MIDDLE AGED; QUALITY OF LIFE; SOCIOECONOMIC FACTORS; SURVIVORS; VINCRISTINE;

EID: 61449214213     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24140     Document Type: Article

References (49)

1. American Cancer Society. Breast Cancer Facts & Figures 2007-2008. Atlanta, Ga; American Cancer Society, Inc.; 2008.
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43-66.
3. Casso D, Buist DS, Taplin S. Quality of life of 5-10 year breast cancer survivors diagnosed between age 40 and 49. Health Qual Life Outcomes. 2004;2:25.
4. Dorval M, Maunsell E, Deschenes L, et al. Long-term, quality of life after breast cancer: comparison of 8-year survivors with population controls. J Clin Oncol. 1998;16:487-494.
5. Dow KH, Ferrell BR, Leigh S, et al. An evaluation of the quality of life among long-term survivors of breast cancer. Breast Cancer Res Treat. 1996;39:261-273.
6. Ganz PA, Desmond KA, Leedham B, et al. Quality of life in long-term disease-free survivors of breast cancer: a follow-up study. J Natl Cancer Inst. 2002;94:39-49.
7. Kornblith AB, Herndon JE, Weiss RB, et al. Long-term adjustment of survivors of early-stage breast carcinoma 20 years after adjuvant chemotherapy. Cancer. 2003;98:679-689.
8. Ahles TA, Saykin AJ, Furstenberg CT, et al. Quality of life of long-term survivors of breast cancer and lymphoma treated with standard-dose chemotherapy or local therapy. J Clin Oncol. 2005;23:4399-4405.
9. Ganz PA, Rowland. JH, Merowitz BE, et al. Impact of different adjuvant therapy strategies on quality of life in breast cancer survivors. Recent Results Cancer Res. 1998;16:501-514.
10. Bottomley A, Therasse P, Piccart M, et al. Health-related quality of life in survivors of locally advanced breast cancer: an international randomised controlled phase III trial. Lancet Oncol. 2005;6:287-294.
11. Ferrell BR, Dow KH, Grant M. Measurement of the quality of life in cancer survivors. Qual Life Res. 1995;4:523-531.
12. Dow KH, Ferrell BR, Haberman MR, Eaton L. The meaning of quality of life in cancer survivorship. Oncol Nurs Forum. 1999;26:519-528.
13. Ersek M, Ferrell BR, Dow KH, Melancon CH. Quality of life in women with ovarian cancer. West J Nurs Res. 1997;19:334-350.
14. Wood WC, Budman DR, Korzun AH, et al. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med. 1994;330:1253-1259.
15. Budman D, Beny DA, Cirrincione CT, et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. J Natl Cancer Inst. 1998;90:1205-1211.
16. Paskett ED, Herndon JE 2nd, Day JM, et al; Cancer and Leukemia Group B. Applying a conceptual model for examining health-related quality of life in long-term breast cancer survivors: CALGB study 79804. Psychooncology. 2008;17:1108-1120.
17. Ware JE, Snow KK, Kosinski M, Gandek B. SF-36 Health Survey Manual and Interpretation Guide. Boston, Mass: New England Medical Center, The Health Institute; 1993.
18. Stewart AL, Ware J. Measure of Functioning and Well-Being: The Medical Outcomes Study Approach. Durham, NC: Duke University Press; 1992.
19. Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas. 1977;1:385-401.
20. Kash KM, Jacobsen PB, Holland JC, Osborne MP, Miller DG. Measuring breast cancer anxiety. Presented at the 42nd Annual Meeting of the Academy of Psychosomatic Medicine, Palm Springs, California, November 16-19, 1995.
21. Lerman C, Trock B, Rimer B. Psychological side effects of breast cancer screening. Health Psychol. 1991;10:259-267.
22. Spielberger CD, Gorsuch RL, Lushene RD. Manual for the State-Trait Anxiety Inventory. Palo Alto, Calif: Consulting Psychologists Press; 1970.
23. Taylor JA. A personality scale of manifest anxiety. J Abnorm Psychol. 1953;48:285-290.
24. Sherbourne CD, Stewart AL. The MOS social support survey. Soc Sci Med. 1991;32:705-714.
25. Anderson D, Bilodeau B, Deshaies G, et al. French-Canadian validation of the MOS social support survey. Can J Cardiol. 2005;21:867-873.
26. Wilcox S, Aragaki A, Mouton CP, et al. The effects of widowhood, on physical and mental health, health behaviors, and health outcomes: the Women's Health Initiative. Health Psychol. 2003;22:513-522.
27. Holland JC, Kash KM, Passik S, et al. A. brief spiritual beliefs inventory for use in quality of life research in lifethreatening illnesses. Psychooncology. 1998;7:460-469.
28. Holland JC, Herndon J, Komblith AB, et al. A sociodemographic data collection model for cooperative clinical trials [abstract]. Proc Am Soc Clin Oncol. 1992;11:157. Abstract 445.
29. Greenberg DB, Komblith AB, Herndon JE, et al. Quality of life of adult leukemia survivors treated on clinical trials of the Cancer and Leukemia Group B from 1971-1988: predictors for later psychological distress. Cancer. 1997;80:1936-1944.
30. George LK, Fillenbaum G. OARS methodology: a decade of experience in geriatric assessment. J Am Geriatrics Soc. 1985;33:607-615.
31. Paskett E. Lymphedema: knowledge, treatment and impact among breast cancer survivors. Breast J. 1999;6:373-378.
32. Crooks V, Waller S, Smith T, Hahn TJ. The use of the Karnofsky performance scale in determining outcomes and risk in geriatric outpatients. J Gerontol. 1991;46:M139-M44.
33. Cohen J. Statistical Power Analysis for the Behavioral Sciences, 2nd ed. New York, NY: Academic Press; 1988.
34. Jonckhere AR. A distribution-free k-sample test against ordered alternatives. Biometrika. 1954;41:133-145.
35. Paskett E, Tatum C, Rushing J, et al. Randomized trial of an intervention to improve mammography utilization among a triracial rural population of women. J Natl Cancer Inst. 2006;98:1226-1237.
36. Broeckel JA, Jacobsen PB, Balducci L, et al. Quality of life after adjuvant chemotherapy for breast cancer. Breast Cancer Res Treat. 2000;62:141-150.
37. Buijs C, Rodenhuis S, Seynaeve CM, et al. Prospective study of long-term impact of adjuvant high-dose and conventional-dose chemotherapy on health-related quality of life. J Clin Oncol. 2007;25:5403-5409.
38. Connor-Spady BL, dimming C, Nabholtz JM, et al. A longitudinal prospective study of health-related quality of life in breast cancer patients following high-dose chemotherapy with autologous blood stem cell transplantation. Bone Marrow Transplant. 2005;36:251-259.
39. Peppercorn J, Herndon J, Komblith AB, et al. Quality of life among patients with stage II and III breast carcinoma randomized to receive high-dose chemotherapy with autologous bone marrow support or intermediate-dose chemotherapy: results from Cancer and Leukemia Group B 9066. Cancer. 2005;104:1580-1589.
40. Fehlauer F, Tribius S, Mehnert A, Rades D. Health-related quality of life in long term breast cancer survivors treated with breast conserving therapy: impact of age at therapy. Breast Cancer Res Treat. 2005;92:217-222.
41. Peuckmann V, Ekholm O, Rasmussen NK, et al. Health-related quality of life in long-term breast cancer survivors: nationwide survey in Denmark. Breast Cancer Res Treat. 2007;104:39-46.
42. Qmprich B, Ronis DL, Martinez-Ramos G. Age at diagnosis and quality of life in breast cancer survivors. Cancer Pract. 2002;10:85-93.
43. Robb C, Haley WE, Balducci L, et al. Impact of breast cancer survivorship on quality of life in older women. Crit Rev Oncol Hematol. 2007;62:84-91.
44. Meeske K, Smith AW, Alfano CM, et al. Fatigue in breast cancer survivors 2 to 5 years post diagnosis: a HEAL Study report. Qual Life Res. 2007;16:947-960.
45. Bower JE, Ganz PA, Desmond KA, et al. Fatigue in long-term breast carcinoma survivors: a longitudinal investigation. Cancer. 2006;106:751-758.
46. Ganz PA. Quality of life across the continuum of breast cancer care. Breast J. 2000;6:324-330.
47. Nieboer P, Buijs C, Rodenhuis S, et al. Fatigue and relating factors in high-risk breast ameer patients treated with adjuvant standard or high-dose chemotherapy: a longitudinal study. J Clin Oncol. 2005;23:8296-8304.
48. Burckhardt CS, Jones KD. Effects of chronic widespread pain on the health status and quality of life of women after breast cancer surgery [serial online]. Health Qual Life Outcomes. 2005;3:30.
49. Schultz PN, Klein MJ, Beck ML et al. Breast cancer: relationship between menopausal symptoms, physiologic health effects of cancer treatment and physical constraints on quality of life in long-term survivors. J Clin Nurs. 2005;14:204-211.